# PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy

Study · id `cardio:ct-nct07174375` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07174375](<https://clinicaltrials.gov/study/NCT07174375>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07174375

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 478 participants.

## Technical summary

Registry record NCT07174375. Randomized; no masking; primary purpose treatment. Start 2025-09-15 (anticipated); primary completion 2027-12-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 478 participants (planned count; ClinicalTrials.gov record NCT07174375, source copy `cardio:ctgov-nct07174375-2025-09-15`, retrieved 2026-10-26)
- Planned start: 2025-09-15 (anticipated) (ClinicalTrials.gov record NCT07174375, source copy `cardio:ctgov-nct07174375-2025-09-15`, retrieved 2026-10-26)
- Primary completion: 2027-12-15 (anticipated) (ClinicalTrials.gov record NCT07174375, source copy `cardio:ctgov-nct07174375-2025-09-15`, retrieved 2026-10-26)
- Completion: 2027-12-15 (anticipated) (ClinicalTrials.gov record NCT07174375, source copy `cardio:ctgov-nct07174375-2025-09-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07174375, source copy `cardio:ctgov-nct07174375-2025-09-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07174375-2025-09-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy
- Acronym: PCSK9-PROVE
- Condition: Acute Ischemic Stroke
- Intervention (Drug): PCSK9 inhibitor
- Lead sponsor: Nanfang Hospital, Southern Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Nanfang Hospital, Southern Medical University (`cardio:org-nanfang-hospital-southern-medical-university`)

## Provenance

Content hash: 01ae28bfca806fe7bfb7fa75094d58384aed291eb59d5338305531367980db67
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
